Fierce Biotech

FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...
BioSpace

From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...
Association of Optometrists (AOP)

Unravelling the puzzle of vision loss in children with arthritis

UK scientists have explored the role of B cells and T cells in the development of uveitis among patients with juvenile ...

B cells play a more sinister role than believed in progression of type 1 diabetes

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the progression of type 1 diabetes (T1D).

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...
The Manila Times

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel (CB-010) ANTLER phase 1 translational and clinical data ...

New method creates acinar cells involved in formation of pancreatic cancer

Organoids are three-dimensional miniature models of organs, grown in a dish. They have become a valuable tool for studying ...
The Malaysian Reserve

Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II

Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme deliverySAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Immusoft ...
The Manila Times

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGeneIFLI contributed up to $9 million to Enterome’s private funding round in 2025Enterome has announced a series of ...